PDCD1 and melanoma: For example, antibodies targeting PD-1 and cytotoxic T-lymphocyte antigen 4, as well as an inhibitor of B-Raf, have all been introduced for the treatment of malignant melanoma [[10], [11], [12],[18], [19], [20]].